



11 December 2024

ASX Announcement

Island Pharmaceuticals granted U.S. patent for ISLA-101

MELBOURNE Australia, 11 December 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to announce that a key patent relating to the Company's lead drug candidate, ISLA-101, has been granted by the United States Patent and Trademark Office (USPTO).

The U.S. patent grant entitled "Method of viral inhibition" was issued under US. Patent No 12,161,610 and has an expiration date of 16 April 2034. The patent covers a method of reducing the severity of one or more symptoms of dengue virus by administering ISLA-101.

CEO of Island Pharmaceuticals, Dr David Foster said, "We are pleased to have been awarded this latest U.S. patent, which bolsters our expanding intellectual property portfolio and provides enhanced protection for our flagship program, ISLA-101, aimed at combating dengue fever. As we continue to advance our Phase 2a/b ISLA-101 clinical trial, our IP program remains fundamental to its success."

Island has licensed the intellectual property for ISLA-101, generated by Monash University. This latest U.S. patent adds to a strong and growing IP portfolio that also includes Australia, Canada, Brazil, and Singapore.

To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page](#) of our website.

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au



About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

For personal use only